---
title: "Ascletis starts Phase II study with ASC30 in US for diabetes treatment. Expect data in Q3 2026. ASC30 shows up to 7.7% weight loss in 13-week study with overweight individuals."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273626909.md"
description: "In the third quarter of 2026, the Phase II study for diabetes treatment is anticipated to reveal its topline data. The ASC30 showed promising results with a placebo-adjusted weight loss of a maximum of 7.7% in a 13-week U.S. Phase II study involving individuals struggling with obesity or being overweight. This indicates a significant improvement in managing weight-related issues."
datetime: "2026-01-26T00:12:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273626909.md)
  - [en](https://longbridge.com/en/news/273626909.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273626909.md)
---

# Ascletis starts Phase II study with ASC30 in US for diabetes treatment. Expect data in Q3 2026. ASC30 shows up to 7.7% weight loss in 13-week study with overweight individuals.

In the third quarter of 2026, the Phase II study for diabetes treatment is anticipated to reveal its topline data. The ASC30 showed promising results with a placebo-adjusted weight loss of a maximum of 7.7% in a 13-week U.S. Phase II study involving individuals struggling with obesity or being overweight. This indicates a significant improvement in managing weight-related issues.

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ATRX.US](https://longbridge.com/en/quote/ATRX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)